Adagene (ADAG) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adagene Inc. showcased promising clinical data at the SITC meeting, highlighting the safety and efficacy of its novel anti-CTLA-4 therapy, ADG126, in combination with pembrolizumab for treating metastatic colorectal cancer. The therapy demonstrated enhanced therapeutic potential and safety profiles, offering hope for improved cancer treatment strategies. These findings underscore ADG126’s potential as a leading therapy in the immunotherapy landscape.
For further insights into ADAG stock, check out TipRanks’ Stock Analysis page.